The estimated Net Worth of Kristin Stephens is at least $47.4 ezer dollars as of 31 March 2024. Kristin Stephens owns over 13,666 units of Syros Pharmaceuticals stock worth over $47,423 and over the last 3 years Kristin sold SYRS stock worth over $0.
Kristin has made over 3 trades of the Syros Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently Kristin exercised 13,666 units of SYRS stock worth $22,002 on 31 March 2024.
The largest trade Kristin's ever made was exercising 17,000 units of Syros Pharmaceuticals stock on 31 October 2023 worth over $27,370. On average, Kristin trades about 4,667 units every 52 days since 2022. As of 31 March 2024 Kristin still owns at least 29,455 units of Syros Pharmaceuticals stock.
You can see the complete history of Kristin Stephens stock trades at the bottom of the page.
Kristin's mailing address filed with the SEC is C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE, MA, 02140.
Over the last 8 years, insiders at Syros Pharmaceuticals have traded over $8,259,551 worth of Syros Pharmaceuticals stock and bought 5,052,185 units worth $51,830,966 . The most active insiders traders include Group, Llc Green Jeremy Red..., Srinivas Akkaraju és Stephane Bancel. On average, Syros Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $135,148. The most recent stock trade was executed by Richard A Young on 28 June 2024, trading 34,837 units of SYRS stock currently worth $178,365.
syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
Syros Pharmaceuticals executives and other stock owners filed with the SEC include: